Novo Nordisk (NYSE: NVO) has announced sweeping price cuts for its blockbuster GLP-1 drugs, Wegovy and Ozempic, offering patients access to the lowest doses for just $199/month. New cash-paying patients will be able to access its anti-obesity treatments at that price for the first two months, the pharmaceutical behemoth confirmed in a press release today.











